医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集

Application

Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL

Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: Application for ICLUSIG ponatinib sNDA Takeda Announces

2024年03月20日

Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS® (Voclosporin) in Japan

Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS® (Voclosporin) in Japan

その他ヘルスバイオテクノロジーヘルスケアヘルス一般腫瘍学製薬　 TimeLine: Application Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug for LUPKYNIS NDA Voclosporin

2023年11月13日

Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review

Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review

その他ヘルスバイオテクノロジーヘルスケアヘルス一般腫瘍学臨床試験製薬　 TimeLine: Application for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review NDA Takeda and HUTCHMED Announce New Drug

2023年05月26日

Aurion Biotech Receives Approval from Japan’s PMDA for New Drug Application

Aurion Biotech Receives Approval from Japan’s PMDA for New Drug Application

バイオテクノロジーヘルスケア眼科医療臨床試験製薬　 TimeLine: Application Aurion Biotech Receives Approval from Japan’s PMDA for New Drug

2023年03月23日

CANbridge Pharmaceuticals CAN108 New Drug Application/Orphan Drug Registration (NDA/ORD) for Alagille Syndrome Accepted by the Taiwan Food and Drug Administration

CANbridge Pharmaceuticals CAN108 New Drug Application/Orphan Drug Registration (NDA/ORD) for Alagille Syndrome Accepted by the Taiwan Food and Drug Administration

バイオテクノロジーヘルスケアヘルス一般腫瘍学臨床試験製薬　 TimeLine: Administration Application NDA ORD Registration

2022年03月29日

CANbridge Pharmaceuticals CAN108 New Drug Application (NDA) for Alagille Syndrome Accepted by China’s National Medical Products Administration

CANbridge Pharmaceuticals CAN108 New Drug Application (NDA) for Alagille Syndrome Accepted by China’s National Medical Products Administration

バイオテクノロジーヘルスケア製薬　 TimeLine: Application CANbridge Pharmaceuticals CAN108 New Drug for Alagille Syndrome Accepted by China’s National Medical Products Administration NDA

2022年01月18日